BETA vs SGRL: Stock Comparison
BETA DRUGS is the larger company by market capitalisation. BETA DRUGS shows a lower P/E and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BETA leads 4; SGRL leads 2 of 9
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | BETA | SGRL |
|---|---|---|
| Live Price | ₹1,805.9 | ₹625.85 |
| Day Change | -1.89% | -0.91% |
| Volume | 15,899 | 8,094 |
| 52-Week High | ₹2,807.9 | ₹749.85 |
| 52-Week Low | ₹990.1 | ₹477.05 |
| Distance from 52W High | -35.69% | -16.54% |
Valuation
| Metric | BETA | SGRL |
|---|---|---|
| Market Cap | ₹2,011 Cr | ₹814 Cr |
| P/E Ratio | 35.56x | 50.76x |
| P/B Ratio | 4.19x | 4.81x |
| EPS | ₹18 | ₹1.27 |
| Book Value | ₹220.09 | ₹126.95 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | BETA | SGRL |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 9.51% | 62.22% |
| Qtr Profit Growth | 16.98% | 45.51% |
Profitability & Leverage
| Metric | BETA | SGRL |
|---|---|---|
| ROE | 14.79% | — |
| ROCE | 18.03% | — |
| Net Margin | 10.78% | 0% |
| Operating Margin | 16.79% | — |
| Debt to Equity | 0.6x | — |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | BETA | SGRL |
|---|---|---|
| Promoter Holding | 58.91%▼ 0.19 pp | 72.84% |
| FII Holding | 1.37%▲ 0.35 pp | 0% |
| DII Holding | 6.45%▲ 0.22 pp | 0.52%▲ 0.52 pp |
| Public Holding | 33.27%▼ 0.38 pp | 26.64%▼ 0.52 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BETA DRUGS and SHREE GANESH REMEDIES.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.